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Abstract: The industrial synthesis of pharmaceutical compounds often involves the use of organic solvents. Unfortunately, these reaction 
media are responsible for organic contaminations in the final product. In recent years, ionic liquids (ILs) have become the “green alterna-
tives” of volatile organic solvents. Thus, the application of ILs instead of conventional reagents offer a new opportunity to solve prob-
lems of environmentally harmful solvents. This mini-review discusses a new application of ILs in laboratory-scale pharmaceutical syn-
thesis. 
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1. INTRODUCTION 
Industrial synthesis of pharmaceutical compounds often in-
volves the use of organic solvents mainly for reasons of cost-
effective procedure and ease of handling. Unfortunately, these reac-
tion media are responsible for organic contamination of the final 
product and are therefore referred to as ‘residual solvents’ or ‘or-
ganic volatile impurities’. The acceptable limits for contaminants 
resulting from the entire drug product manufacturing process have 
been specified in pharmacopoeias and the International Conference 
on Harmonization (ICH) of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use [1]. The ICH guideline 
distinguishes four classes of residual solvents in drug substances: 
solvents to be avoided, solvents to be limited, solvents with low 
toxic potential and solvents without adequate toxicological data. 
From the toxicological point of view, genotoxic impurities (GTIs) 
are the most dangerous contaminants for human health. Exposure to 
even low levels of such impurities present in the final active phar-
maceutical ingredient (API) may induce genetic mutations and may 
potentially cause cancer in humans [2,3]. However, regardless of 
the solvent class, it is important to explore the possible opportuni-
ties to reduce or avoid the use of harmful solvents in the manufac-
turing process of pharmaceuticals. 
The use of ionic liquids (ILs) as non-conventional media in 
chemical synthesis is increasing attention because of their physical 
and chemical properties. Their growing application in organic 
chemistry stems from their favourable physicochemical properties, 
such as the lack of vapour pressure, good thermal and chemical 
stability and very good dissolution properties of both organic and 
inorganic compounds. ILs are generally organic salts composed of 
various organic or inorganic cations and anions with a melting point 
at or near room temperature. They are therefore liquid at room tem-
perature and are known by many synonyms, such as room-
temperature ionic liquids (RTILs), liquid organic salts, low-
temperature molten salts or ambient-temperature molten salts [4]. 
They are also referred to as neoteric solvents, meaning new types of 
solvent or materials that are finding new application as solvents. 
ILs, being ‘designer solvents’, are convenient to use because of 
their combined cationic and anionic properties, which can be inde-
pendently modified [5]. The ability to modify their properties, e.g. 
viscosity, density, solvent miscibility and melting point, results in 
their flexibility in the design of new functional materials [6-8]. ILs 
are also called ‘environmentally friendly’ and have been suggested 
as ideal replacements for volatile organic solvents [5,9]. The appli-
cation of ‘green’ solvents, such as ionic liquids, in the 
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pharmaceutical industry is currently being extensively investigated 
at the laboratory scale [10]. This mini-review discusses a new ap-
plication of ILs in pharmacy. 
2. THE APPLICATION OF IONIC LIQUIDS IN PHARMA-
CEUTICAL SYNTHESIS 
ILs have many desirable properties of interest to the pharma-
ceutical industry. Reactions in ILs are often faster and easier to 
carry out than those in conventional organic solvents and usually 
require no special apparatus or methodologies. It should, however, 
be emphasised that the thermodynamics and kinetics of the reac-
tions carried out in ILs are different from those carried out in con-
ventional solvents. Synthesis with the use of ILs mainly concerns 
liquid organic salts composed of the 1,3-dialkylimidazolium and N-
alkylpyridinum cation and a non-coordinating anion (Fig. 1) [11]. 
However, no universal catalytic system exists for all syntheses and 
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Fig. (1). The most commonly used ILs in chemical synthesis: a) the 1,3-
dialkylimidazolium cation and b) the N-alkylpyridinum cation. 
In recent years, ILs have attracted an increasing attention as re-
action media in enzymatic processes because of the very high en-
zymatic activity and stability in these ‘green’ solvents. Generally, 
there are three ways in which ILs can be involved in the biocata-
lytic process: (i) as pure solvents in monophasic systems, various 
water-immiscible ILs (e.g. 1-ethyl-3-methylimidazolium hex-
afluorophosphate ([bmim][PF6]), (ii) as water-miscible ILs in mo-
nophasic systems—co-solvents in aqueous systems (e.g. N-
ethylpyridinium trifluoroacetate), or (iii) as pure ILs in non-aqueous 
biphasic systems (used as liquid or solid enzyme immobilisation 
supports) [13-15]. However, 1,3-dialkylimidazolium- and 
N-alkylpyridinum-based ILs have also been considered in biocata-
lysis. 
The properties of imidazolium-based ILs properties make it 
possible to use the solvents as a direct replacement for conventional 
solvents in multiphase bioprocess operations [16]. ILs containing 
the hexafluorophosphate anion (PF6) may form triphasic mixtures 
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with alkanes, alkylated aromatic compounds and water. The suc-
cessful use of [bmim] [PF6] in liquid-liquid extraction of the antibi-
otic erythromycin-A and in Rhodococcus R312 catalysed biotrans-
formation of 1,3-dicyanobenzene (1,3-DCB) in a liquid-liquid, two-
phase system have been described [17]. The advantage of multipha-
sic behaviour of ILs over multiphase processes employing conven-
tional mixtures has been demonstrated and the issues associated 
with the toxicity and flammability of other organic solvents empha-
sised. However, further research is required for a rational selection 
or design of ILs to improve their efficacy in particular transforma-
tion processes.  
ILs in the Synthesis of Antiviral, Antileishmanial and Antipara-
sitic Drugs 
The search for novel antiviral nucleoside analogues has resulted 
in the design of ILs which provide high solubility to nucleosides 
and have been found to be an efficient reaction medium giving high 
yields under ambient conditions [18,19]. Syntheses of nucleoside-
based antiviral drugs (Brivudine, Stavudine, Trifluridine) using 
such ionic liquids, as 1-methoxyethyl-3-methylimidazolium 
methanesulfonate ([moemim][Ms]), 1-methoxyethyl-3-methyl- 
imidazolium trifluoroacetate ([moemim][TFA]) and 1-butyl-3-
methylilidazolium trifluoroacetate ([bmim][TFA]) as the reaction 
media have successfully been performed. For instance, selected ILs 
as reaction media for the synthesis of trifluridine (5-
trifluoromethyl-2’-deoxyuridine, TFT) have given the final product 
in 90-91% yields as a single product with the reaction time in the 
range of 20-25 min (Diagram 1) [20]. All the ILs made it possible 
to obtain TFT with high purity and a 10-fold decrease in solvent 
consumption compared to the standard reaction media, pyri-
dine/DMAP or acetonitrile/Et3N/DMAP.  
Shaabani et al. [21,22] studied drugs based on acyclic nucleo-
side analogues, which have a potential antiviral activity and re-
ported an efficient and ‘environmentally friendly’ approach for the 
synthesis of 3-amino-imidazo[1,2- ]pyridines with high antiviral 
activity using the 1-butyl-3-methylimidazolium bromide 
([bmim][Br]) ionic liquid. Replacing the commonly used organic 
solvents by the readily available imidazolium bromide improves the 
synthesis of the side-chain-modified imidazo[1,2- ]pyridinic de-
rivative. The derivative was synthesized by three-component con-
densation of an aldehyde 1, 2-amino-5-methylpyridine or 2-amino-
5-bromopyridine 2 and isocyanide 3 in ([bmim][Br]) at room 
temperature with very high yields in the range of 70–99% (Diagram 
2). In addition, the removal of [bmim][Br] from the reaction media 

































1 2 3 4
(a) (b)
Solvents                        Reaction (a)                      Reaction (b)
                               time (min.)/yield1 (%)       time (min.)/yield1 (%)
[moemim][Ms]                 20/91                              60/35
[moemim][TFA]               25/90                              60/40





















1 2 3 4 a-k
70-99%
Entry                 R1                  R2                        R3               Product                Yield (%)
1                      C6H5                 Br                     C6H11                 4a                          98
2                       C6H5               CH3                  C6H11                  4b                          98
3                    4-CH3C6H4       CH3                  C6H11                   4c                          99
4                    4-ClC6H4           CH3                  C6H11                  4d                          92
5                    3-O2NC6H4       CH3                  C6H11                   4e                          99
6                    4-C5H4N           CH3                   C6H11                 4f                           97
7                       C6H5             CH3                 (CH3)3C                4g                          99
8                       C6H5             CH3                 (CH3)3C               4h                           90
9                    4-CH3C6H4       CH3                 (CH3)3C                4i                           86
10                     C6H5             CH3          2,6-(CH3)2C6H3           4j                           72
11                 4-CH3C6H4       CH3          2,6-(CH3)2C6H3          4k                          70
 
Diagram 2. Synthesis of 3-aminoimidazo[1,2- ]pyridines by three-component condensation with the use of [bmim][Br] as the reaction media.  
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possible by washing with water and evaporating the solvent under 
vacuum. Also, the advantage of ILs as reaction additives has been 
confirmed by the reaction of p-methylbenzaldehyde, 2-amino-5-
methylpyridine and cyclohexyl isocyanide in the absence of 
[bmim][Br]. The yield of product was 25% at room temperature 
after 12 hours.  
 ‘Hybrids compounds’ have also been applied in this drug class. 
Fan et
 
al. [23] have developed a novel, green efficient synthesis of 
hybrid compounds: pyrimidine nucleosides combined with 
pyrano[3,2-c]pyridines and pyrimidine nucleosides combined with 
pyrano[4,3-c]pyranes, as potential antiviral and antileishmanial 
agents (Diagram 3). As a reaction medium in this procedure, they 
used the IL [bmim][BF4] without any catalyst, achieving high 
yields in compared to the methods reported in the literature and, 
additionally, the possibility of easy recovery and reuse of the sol-
vent. A study investigating the use of ‘hybrids compound’ and ILs 
as reaction media has also been performed by Zhang et al. [24]. 
They reported a novel and efficient catalyst procedure that required 
no catalyst for the development of potentially antiparasitic drugs. 
They synthesised a series of pyrimidine nucleoside-thiazolini-4-one 
hybrids using 1-butyl-3-methyl-imidazolium hexafluorophosphate 























1 2 3 4
Entry      R                   X              Product          Time (h)      Yielda (%)
1           COCH3         N-CH3          4a                     3                 85
2           COCH3         N-H               4b                     3                  80
3           COCH3         N-C2H5          4c                    3                  82
4            COCH3            O               4d                    4                   79
5               H               N-CH3           4e                    2                  86
6                H               N-H               4f                    3                  82
7               H               N-C2H5          4g                    3                  80
8               H                 O                 4h                    4                  78
a) isolated yields
 


























Entry              R                     Product         Time (h)      Yielda (%)
1                  Ph                        4a                   6                  70
2                  p-MeC6H4           4b                   5                   75
3                  p-BrC6H4            4c                    6                  58
4                  p-ClC6H4            4d                    6                  62
5                  p-FC6H4              4e                   6                   65
6                 m-NO2C6H4         4f                    6                   60
7                 2-C5H4N              4g                    8                  53
8                 6-Br-2-C5H4       4h                    8                  50 
a) isolated yields
 
Diagram 4. Synthesis of pyrimidine nucleoside-thiazolini-4-one hybrids using [bmim][PF6] as the reaction medium. 
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simple and straightforward and makes it possible to avoid the use of 
volatile and poisonous conventional organic solvents. 
ILs in Synthesis of Anticancer Drugs 
ILs have also been used in the synthesis of drugs with a promis-
ing antitumour potential. Zaidlewicz et al. [25,26] used ionic liq-
uids [bmim][X] (bmim= 1–butyl-3-methylimidazole, X=BF4, PF6) 
in the synthesis of L-4-boronophenylalanine (L-BPA), a clinically 
approved drug in boron neutron capture therapy (BNCT) (Diagram 
5). BNCT is based on boron-containing compounds that target tu-
mour tissue using a suitable boron carrier. Cross-coupling with 
pinacolborane with the use of protected p-iodophenylalanine was 
performed in an BF4 ionic liquid as part of the search for new alter-
native protocols of efficient synthesis of boron compounds that 
might offer therapeutic advantage. The use of “non-volatile” sol-
vents enabled the synthesis of BPA and its analogues with a good 
yield (82–89%) after 20 min.  
There is also a report of another synthesis of compounds with 
antitumor activities that used ILs as the reaction medium. Kurata et 
al. [27] developed a novel, efficient biocatalytic procedure provid-
ing various caffeic acid phenethyl ester (CAPE) analogues exerting 
potential antiproliferative effects on human tumour cells by using 
Candida antarctica lipase B (Novozyme 435) in 1-butyl-3-
methylimidazolium bis(trifluoromethylsulfonyl)imide 
([bmim][NTf2]) as the solvent (Diagram 6). A comparable conver-
sion yield was obtained for CAPE analogues produced with the use 
of ([bmim][NTf2]) and CAPE synthesised in isooctane (yield of 
91,65%). 
ILs in the Synthesis of Non-steroid Anti-inflammatory Drug 
(NSAIDs) 
The application of ILs offers an alternative in the synthesis of 
all the conventional non-steroid anti-inflammatory drug (NSAIDs). 
The synthesis of pravadoline has already been performed in an 
ionic liquid by combined Friedel-Crafts reaction and nucleophilic 
displacement reaction (Diagram 7). Numerous imidazolium-based 
ILs have been tested to improve the efficiency of the reaction. The 

































Compound                R                    Conversion yields (%)
       1           2-cyclohexylethly                     97,6
       2               3-cyclohexylpropyl                93,8
       3               4-phenylbutyl                         96,7
       4           5-phenylpentyl                          84,0
 
Diagram 6. Production of CAPE analogues in the transesterification reaction of methyl caffeate with various alcohols using Candida antarctica lipase B (No-




























Diagram 7. Synthesis of pravadoline in [bmim][PF6] (R = OCH3). 
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morpholino)-2-chloroethane has been achieved in 1-butyl-2,3-
dimethylimidazolium hexafluorophosphate ([bmim][PF6]), while 
the best yield of Friedel-Crafts acylation of the product from the 
nucleophilic displacement reaction has been obtained in 
[bmim][PF6] at 150˚C. It is interesting to note that no catalyst or 
strictly anhydrous conditions are required when using the ILs as the 
reaction media [16, 28].  
The synthesis of another NSAID, (S)-naproxen, can be per-
formed in the presence of in situ or performed Ru-BINAP catalyst 
precursors immobilised in 1-n-butyl-3-methylimidazolium tetra-
fluoroborate IL phase with similar optical yields in comparison with 
the homogeneous reaction (Diagram 8). One of the advantages of 
the ILs involves the possibility of using and recycling a homoge-
nous transition-metal catalyst without significant changes in activity 
or selectivity [29]. A further study on optimisation and extension to 
other chiral pharmaceutical compounds is ongoing [16].  
Ibuprofen, commercially available as a racemate, is one of the 
most popular NSAIDs. However, the (S)-(+)-enantiomer has been 
proved to be 160 times more active than the (R)-(–)-enantiomer 
[30]. Numerous alternative biosyntheses with the use of ILs have 
therefore been designed to obtain a more enantioselective product 
compared to the conventional solvent systems.  
Candida rugosa lipase was shown to posses a comparable or 
higher activity and enantioselectivity in some ILs compared to 
those in isooctane (Diagram 9) [31]. It was concluded that 
[bmim][PF6] could be applied to substitute the conventional organic 
solvent. Contesini et al. [32] described the effect of commercially 
available lipases and two native lipases from Aspergillus niger and 
Aspergillus terrus on the kinetic resolution of (R,S)-ibuprofen in 
systems containing [bmim][PF6] and [bmim][BF4]. The results 
indicated that the commercial Candida rugosa and native Aspergil-
lus niger lipases exhibited the highest enantioselectivity and esterfi-
cation activity in a two-phase system containing isooctane and 
[bmim][PF6] (1:1) compared with a system in pure isooctane. 
ILs in the Synthesis of Antidepressant Drugs 
(S)-3-chloro-1-phenyl-1-propanone ((S)-CPPO) obtained from 
enantiopure (S)-3-chloro-1-phenyl-1-propanol (3-CPP), is often 
used as a substrate in the synthesis of the most popular drugs em-
ployed in the treatment of depressive disorders (fluoxetine, to-
moxetine) (Fig. 2). Enantioselective enzymatic reduction using a 
variety of reductases and dehydrogenases enables asymmetric syn-
thesis of pure chiral compounds. However, the problem in this sys-
tem is the low solubility of 3-CPP in the aqueous phase resulting in 















Fig. (2). A model of a biphasic reaction system used in the manufacture of 
(S)-CPPO. 
The entire cell-ionic liquid biphasic system enables the synthe-
sis of water-insoluble chiral compounds. A system based on recom-
binant Escherichia coli cells co-expressing reductase and glucose 
























                                   C(%)         ees (%)          E
  
Isooctane                     29               33             13.0
[bmim][PF6]                30               38             24.1
 
Diagram 9. Kinetic resolution of (R,S)-ibuprofen with an enzyme.  
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(S)-CPPO. A variety of ILs were tested in aqueous two-phase sys-
tems to increase the solubility of 3-CPP. Finally, ([bmim][NTf2]) 
was selected as the optimal modifier which dramatically increased 
the concentration of the substrate and the yield of the target com-
pound ((S)-CPPO) with an enantiomeric excess of >99% [33].  
3. CONCLUSIONS 
In recent years, ILs have become ‘green alternatives’ of the 
volatile organic solvents. Because of their properties ILs have a 
great potential as reaction media in a wide range of biocatalytic and 
conventional syntheses. The reaction yields with the use of ILs are 
generally comparable or higher than those obtained in conventional 
organic solvents. Sometimes the use of ILs as a component of a 
multiphasic system makes it possible for a reaction to occur that 
would not have occurred in the absence of the ILs in a conventional 
reaction environment. Also, thermal stability in mono- and multi-
phase IL based systems and regio- or enantioselectivities have been 
observed [11]. Additionally, products and by-products can be sepa-
rated from such liquids by distillation or solvent extraction with 
either an aqueous or an organic phase [28]. Furthermore, the use of 
ILs leads to a cost reduction because these solvents can often be 
recycled and reused [15].  
The rapid growth of interest in the application of ILs in most 
areas of chemistry is reasonable in view of their unique properties. 
The use of ILs as ‘green chemistry’ instead of the conventional 
environmentally harmful agents offers new opportunities to solve 
the problems of difficult chemical synthesis of different substances. 
These solvents are currently employed in laboratory-scale pharma-
ceutical synthesis. Only time will show the real potential of ILs. 
Further research will definitely be required to verify the feasibility 
of developing the laboratory procedures in the pharmaceutical in-
dustry.  
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